

**Vaccination Coverage Statistics for Children in Northern Ireland:
Completed Primary Immunisations by 24 months**

| Quarter* | Year | No. in cohort | **DTaP/IPV/Hib/HepB | MMR1 | MenC | PCV Booster | Hib/MenC | MenB3 |
|-----------|------|---------------|---------------------|-------|-------|-------------|----------|-------|
| Jan-Mar | 2011 | 5983 | 98.9% | 93.0% | 97.7% | 93.5% | 95.9% | ~ |
| Apr-June | 2011 | 6145 | 98.4% | 92.7% | 96.9% | 93.1% | 95.3% | ~ |
| July-Sept | 2011 | 6403 | 98.5% | 92.8% | 96.8% | 93.5% | 95.4% | ~ |
| Oct-Dec | 2011 | 6240 | 98.3% | 93.3% | 96.9% | 94.2% | 95.7% | ~ |
| Jan-Mar | 2012 | 6182 | 98.5% | 93.7% | 97.1% | 94.8% | 95.9% | ~ |
| Apr-June | 2012 | 6148 | 98.6% | 95.3% | 97.1% | 95.8% | 95.7% | ~ |
| July-Sept | 2012 | 6505 | 98.6% | 95.4% | 97.2% | 95.5% | 95.7% | ~ |
| Oct-Dec | 2012 | 6562 | 98.7% | 95.9% | 97.2% | 96.4% | 96.5% | ~ |
| Jan-Mar | 2013 | 6159 | 98.4% | 95.3% | 97.1% | 95.8% | 95.9% | ~ |
| Apr-June | 2013 | 6027 | 98.7% | 96.1% | ~ | 96.2% | 96.4% | ~ |
| July-Sept | 2013 | 6576 | 98.8% | 96.0% | ~ | 95.9% | 96.0% | ~ |
| Oct-Dec | 2013 | 6260 | 98.6% | 96.3% | ~ | 96.3% | 96.5% | ~ |
| Jan-Mar | 2014 | 6229 | 98.5% | 96.1% | ~ | 96.1% | 96.3% | ~ |
| Apr-June | 2014 | 6185 | 98.9% | 96.4% | ~ | 96.2% | 96.3% | ~ |
| July-Sept | 2014 | 6443 | 98.7% | 96.4% | ~ | 96.8% | 96.5% | ~ |
| Oct-Dec | 2014 | 6421 | 98.4% | 95.5% | ~ | 95.9% | 95.9% | ~ |
| Jan-Mar | 2015 | 5816 | 97.9% | 94.5% | ~ | 95.0% | 94.7% | ~ |
| Apr-June | 2015 | 5914 | 98.2% | 96.1% | ~ | 95.9% | 95.8% | ~ |
| July-Sept | 2015 | 6466 | 98.3% | 95.8% | ~ | 95.8% | 95.8% | ~ |
| Oct-Dec | 2015 | 5959 | 98.3% | 95.5% | ~ | 96.0% | 95.9% | ~ |
| Jan-Mar | 2016 | 5923 | 98.3% | 95.9% | ~ | 96.3% | 95.9% | ~ |
| Apr-June | 2016 | 5978 | 97.9% | 95.0% | ~ | 95.5% | 95.3% | ~ |
| July-Sept | 2016 | 6521 | 97.9% | 94.5% | ~ | 94.9% | 95.0% | ~ |
| Oct-Dec | 2016 | 6162 | 97.9% | 94.8% | ~ | 95.2% | 94.9% | ~ |
| Jan-Mar | 2017 | 5765 | 98.0% | 94.7% | ~ | 95.0% | 94.8% | ~ |
| Apr-June | 2017 | 5937 | 97.9% | 94.8% | ~ | 95.1% | 95.0% | ~ |
| July-Sept | 2017 | 6524 | 97.9% | 94.6% | ~ | 94.9% | 94.8% | 94.1% |
| Oct-Dec | 2017 | 6238 | 97.7% | 93.8% | ~ | 94.6% | 94.4% | 94.1% |
| Jan-Mar | 2018 | 5781 | 98.0% | 94.6% | ~ | 95.7% | 95.0% | 94.6% |
| Apr-June | 2018 | 5995 | 97.5% | 93.4% | ~ | 93.8% | 93.7% | 93.4% |
| July-Sept | 2018 | 6363 | 97.4% | 93.6% | ~ | 94.1% | 93.9% | 93.7% |
| Oct-Dec | 2018 | 6133 | 96.9% | 92.3% | ~ | 92.5% | 92.5% | 92.2% |
| Jan-Mar | 2019 | 5709 | 96.5% | 91.2% | ~ | 92.5% | 91.7% | 91.4% |
| Apr-June | 2019 | 5656 | 95.8% | 91.4% | ~ | 91.8% | 91.6% | 91.6% |
| July-Sept | 2019 | 6140 | 96.0% | 92.1% | ~ | 92.5% | 92.2% | 92.2% |
| Oct-Dec | 2019 | 5883 | 96.0% | 92.7% | ~ | 93.5% | 92.8% | 92.6% |
| Jan-Mar | 2020 | 5431 | 95.6% | 92.2% | ~ | 92.6% | 92.3% | 92.1% |
| Apr-June | 2020 | 5806 | 95.5% | 92.2% | ~ | 92.6% | 92.2% | 92.3% |
| July-Sept | 2020 | 6080 | 95.8% | 91.9% | ~ | 92.3% | 92.1% | 91.8% |
| Oct-Dec | 2020 | 5743 | 96.0% | 92.3% | ~ | 92.7% | 92.5% | 92.2% |
| Jan-Mar | 2021 | 5451 | 96.2% | 91.5% | ~ | 92.0% | 91.7% | 91.2% |
| Apr-June | 2021 | 5549 | 95.9% | 92.4% | ~ | 92.9% | 92.6% | 91.9% |
| July-Sept | 2021 | 5993 | 95.4% | 91.1% | ~ | 91.5% | 91.5% | 90.5% |
| Oct-Dec | 2021 | 5651 | 94.7% | 91.3% | ~ | 91.5% | 91.3% | 90.4% |
| Jan-Mar | 2022 | 5315 | 95.2% | 91.9% | ~ | 92.0% | 92.0% | 91.3% |
| Apr-June | 2022 | 5272 | 94.4% | 90.5% | ~ | 90.6% | 90.6% | 89.5% |
| July-Sept | 2022 | 5731 | 94.0% | 89.4% | ~ | 89.6% | 89.5% | 88.9% |
| Oct-Dec | 2022 | 5434 | 94.4% | 89.5% | ~ | 90.2% | 89.8% | 89.0% |
| Jan-Mar | 2023 | 5384 | 94.0% | 89.4% | ~ | 91.8% | 89.8% | 89.2% |
| Apr-June | 2023 | 5342 | 93.8% | 89.3% | ~ | 89.8% | 89.8% | 88.6% |
| Jul-Sept | 2023 | 6007 | 93.1% | 88.8% | ~ | 89.1% | 89.0% | 88.1% |
| Oct-Dec | 2023 | 5646 | 93.7% | 89.5% | ~ | 89.7% | 89.7% | 88.7% |
| Jan-Mar | 2024 | 5159 | 93.6% | 89.3% | ~ | 89.4% | 89.4% | 88.3% |
| Apr-June | 2024 | 5117 | 93.6% | 89.9% | ~ | 90.0% | 90.1% | 89.0% |
| Jul-Sept | 2024 | 5478 | 93.6% | 90.3% | ~ | 90.8% | 90.2% | 89.2% |
| Oct-Dec | 2024 | 5217 | 92.8% | 89.1% | ~ | 91.5% | 88.9% | 87.7% |
| Jan-Mar | 2025 | 4896 | 92.7% | 88.7% | ~ | 88.9% | 88.8% | 87.4% |

* children were 24 months old during this quarter

****DTaP/IPV/Hib/HepB**

Dip3 = Diphtheria (DTaP/IPV/Hib3 vaccine) (3 doses) replaced with (DTaP/IPV/Hib/HepB3 vaccine) from August 2017
Tet3 = Tetanus (DTaP/IPV/Hib3 vaccine) (3 doses) replaced with (DTaP/IPV/Hib/HepB3 vaccine) from August 2017
Pert3 = Pertussis (DTaP/IPV/Hib3 vaccine) (3 doses) replaced with (DTaP/IPV/Hib/HepB3 vaccine) from August 2017
Pol (IPV)3 = Polio (DTaP/IPV/Hib3 vaccine) (3 doses) replaced with (DTaP/IPV/Hib/HepB3 vaccine) from August 2017
Hib3 = *Haemophilus Influenzae* type b (DTaP/IPV/Hib3 vaccine) (3 doses) replaced with (DTaP/IPV/Hib/HepB3 vaccine) from August 20
HepB3 = Hepatitis B (DTaP/IPV/Hib/HepB3 vaccine) (3 doses) (introduced in August 2017)Reporting commenced Jan-Mar 2020

Infant MenC = ~ Meningococcal serogroup C conjugate vaccine (2 doses under 12 months) reporting ceased in April 2013
PCV Booster = Pneumococcal conjugate booster vaccine (1 dose over 12 months) (introduced Sept 2006)
MMR1 = Measles, mumps, and rubella vaccine (1 dose)
Hib/MenC = Hib/MenC booster vaccine (1 dose) (introduced September 2006)
MenB3 = Meningococcal serogroup B vaccine (3 doses) (introduced Sept 2015)

**Vaccination Coverage Statistics for Children in BHSCT:
Completed Primary Immunisations by 24 months**

| Quarter* | Year | No. in cohort | **DTap/IPV/Hib/HepB | MMR1 | MenC | PCV Booster | Hib/MenC | MenB3 |
|-----------|------|---------------|---------------------|-------|-------|-------------|----------|-------|
| Jan-Mar | 2011 | 1086 | 98.2% | 88.8% | 96.1% | 88.6% | 92.6% | ~ |
| Apr-June | 2011 | 1141 | 97.1% | 88.9% | 94.7% | 89.8% | 92.4% | ~ |
| July-Sept | 2011 | 1185 | 96.6% | 88.5% | 94.3% | 89.5% | 91.9% | ~ |
| Oct-Dec | 2011 | 1153 | 96.4% | 89.4% | 95.1% | 89.9% | 92.5% | ~ |
| Jan-Mar | 2012 | 1066 | 97.4% | 89.7% | 94.6% | 90.4% | 92.5% | ~ |
| Apr-June | 2012 | 1141 | 98.1% | 92.8% | 95.7% | 92.7% | 93.1% | ~ |
| July-Sept | 2012 | 1218 | 96.9% | 92.5% | 94.6% | 92.2% | 92.5% | ~ |
| Oct-Dec | 2012 | 1313 | 97.3% | 93.6% | 94.5% | 94.0% | 94.1% | ~ |
| Jan-Mar | 2013 | 1158 | 97.4% | 93.1% | 94.8% | 93.3% | 93.8% | ~ |
| Apr-June | 2013 | 1092 | 97.8% | 93.7% | ~ | 93.5% | 93.4% | ~ |
| July-Sept | 2013 | 1264 | 97.9% | 94.9% | ~ | 94.2% | 94.0% | ~ |
| Oct-Dec | 2013 | 1214 | 97.2% | 93.7% | ~ | 92.6% | 93.3% | ~ |
| Jan-Mar | 2014 | 1228 | 97.0% | 93.7% | ~ | 93.2% | 93.5% | ~ |
| Apr-June | 2014 | 1163 | 98.1% | 94.5% | ~ | 93.4% | 94.0% | ~ |
| July-Sept | 2014 | 1211 | 97.2% | 94.0% | ~ | 95.2% | 93.9% | ~ |
| Oct-Dec | 2014 | 1218 | 97.0% | 93.5% | ~ | 93.4% | 93.1% | ~ |
| Jan-Mar | 2015 | 1111 | 96.0% | 90.9% | ~ | 91.9% | 91.0% | ~ |
| Apr-June | 2015 | 1115 | 96.3% | 93.1% | ~ | 92.6% | 92.3% | ~ |
| July-Sept | 2015 | 1258 | 97.0% | 93.7% | ~ | 93.2% | 93.3% | ~ |
| Oct-Dec | 2015 | 1118 | 96.1% | 91.8% | ~ | 91.8% | 91.6% | ~ |
| Jan-Mar | 2016 | 1097 | 97.1% | 93.6% | ~ | 93.7% | 93.5% | ~ |
| Apr-June | 2016 | 1155 | 96.6% | 91.6% | ~ | 91.8% | 91.6% | ~ |
| July-Sept | 2016 | 1190 | 96.5% | 90.0% | ~ | 90.4% | 90.0% | ~ |
| Oct-Dec | 2016 | 1145 | 95.3% | 89.8% | ~ | 90.1% | 89.8% | ~ |
| Jan-Mar | 2017 | 1105 | 96.5% | 90.6% | ~ | 90.5% | 90.0% | ~ |
| Apr-June | 2017 | 1121 | 95.9% | 92.3% | ~ | 92.1% | 91.9% | ~ |
| July-Sept | 2017 | 1151 | 96.4% | 91.3% | ~ | 91.1% | 90.4% | 90.0% |
| Oct-Dec | 2017 | 1127 | 95.0% | 88.7% | ~ | 89.1% | 89.0% | 88.3% |
| Jan-Mar | 2018 | 1058 | 95.8% | 91.4% | ~ | 91.6% | 91.2% | 91.1% |
| Apr-June | 2018 | 1091 | 95.1% | 89.2% | ~ | 89.5% | 88.9% | 88.9% |
| July-Sept | 2018 | 1161 | 95.1% | 89.0% | ~ | 88.8% | 88.5% | 88.2% |
| Oct-Dec | 2018 | 1194 | 94.9% | 86.8% | ~ | 86.9% | 86.9% | 86.3% |
| Jan-Mar | 2019 | 1046 | 93.9% | 85.3% | ~ | 86.3% | 85.5% | 85.4% |
| Apr-June | 2019 | 995 | 90.3% | 82.8% | ~ | 83.7% | 83.0% | 83.0% |
| July-Sept | 2019 | 1086 | 92.1% | 84.9% | ~ | 85.5% | 85.0% | 85.1% |
| Oct-Dec | 2019 | 1080 | 91.7% | 87.2% | ~ | 87.4% | 86.8% | 86.6% |
| Jan-Mar | 2020 | 1014 | 91.9% | 86.0% | ~ | 87.0% | 85.7% | 86.0% |
| Apr-June | 2020 | 1057 | 92.2% | 86.7% | ~ | 87.1% | 86.1% | 86.0% |
| July-Sept | 2020 | 1161 | 92.5% | 85.5% | ~ | 85.6% | 85.1% | 85.3% |
| Oct-Dec | 2020 | 1067 | 93.1% | 87.9% | ~ | 88.3% | 88.1% | 87.6% |
| Jan-Mar | 2021 | 986 | 93.4% | 85.2% | ~ | 85.3% | 84.6% | 83.3% |
| Apr-June | 2021 | 1053 | 93.2% | 86.1% | ~ | 87.0% | 86.2% | 84.8% |
| July-Sept | 2021 | 1127 | 92.4% | 83.4% | ~ | 83.8% | 83.8% | 82.2% |
| Oct-Dec | 2021 | 1055 | 90.0% | 84.1% | ~ | 83.8% | 84.0% | 82.4% |
| Jan-Mar | 2022 | 983 | 90.8% | 85.0% | ~ | 84.2% | 84.8% | 83.2% |
| Apr-June | 2022 | 1005 | 89.1% | 81.1% | ~ | 81.1% | 80.7% | 78.7% |
| July-Sept | 2022 | 1083 | 88.6% | 81.1% | ~ | 80.6% | 80.7% | 79.1% |
| Oct-Dec | 2022 | 1015 | 88.5% | 80.0% | ~ | 79.6% | 80.1% | 77.6% |
| Jan-Mar | 2023 | 1015 | 87.8% | 79.8% | ~ | 90.4% | 80.2% | 78.3% |
| Apr-June | 2023 | 960 | 86.1% | 79.0% | ~ | 78.9% | 79.0% | 75.6% |
| Jul-Sept | 2023 | 1113 | 88.8% | 82.8% | ~ | 82.4% | 82.3% | 80.0% |
| Oct-Dec | 2023 | 1056 | 88.3% | 82.5% | ~ | 82.2% | 82.7% | 80.2% |
| Jan-Mar | 2024 | 891 | 89.0% | 84.6% | ~ | 83.8% | 84.0% | 81.0% |
| Apr-June | 2024 | 924 | 89.9% | 84.8% | ~ | 85.0% | 85.0% | 82.3% |
| Jul-Sept | 2024 | 1023 | 89.1% | 83.6% | ~ | 83.1% | 83.0% | 81.3% |
| Oct-Dec | 2024 | 959 | 89.2% | 84.3% | ~ | 83.7% | 83.4% | 81.4% |
| Jan-Mar | 2025 | 896 | 88.1% | 81.9% | ~ | 81.5% | 81.9% | 79.7% |

* children were 24 months old during this quarter

****DTap/IPV/Hib/HepB**

Dip3 = Diphtheria (DTaP/IPV/Hib3 vaccine) (3 doses) replaced with (DTaP/IPV/Hib/HepB3 vaccine) from August 2017
Tet3 = Tetanus (DTaP/IPV/Hib3 vaccine) (3 doses) replaced with (DTaP/IPV/Hib/HepB3 vaccine) from August 2017
Pert3 = Pertussis (DTaP/IPV/Hib3 vaccine) (3 doses) replaced with (DTaP/IPV/Hib/HepB3 vaccine) from August 2017
Pol (IPV)3 = Polio (DTaP/IPV/Hib3 vaccine) (3 doses) replaced with (DTaP/IPV/Hib/HepB3 vaccine) from August 2017
Hib3 = *Haemophilus Influenzae* type b (DTaP/IPV/Hib3 vaccine) (3 doses) replaced with (DTaP/IPV/Hib/HepB3 vaccine) f
HepB3 = Hepatitis B (DTaP/IPV/Hib/HepB3 vaccine) (3 doses) (introduced in August 2017)Reporting commenced Jan-Mar :

Infant MenC = ~ Meningococcal serogroup C conjugate vaccine (2 doses under 12 months) reporting ceased in April 2013
PCV Booster = Pneumococcal conjugate booster vaccine (1 dose over 12 months) (introduced Sept 2006)
MMR1 = Measles, mumps, and rubella vaccine (1 dose)
Hib/MenC = Hib/MenC booster vaccine (1 dose) (introduced September 2006)
MenB3 = Meningococcal serogroup B vaccine (3 doses) (introduced Sept 2015)

**Vaccination Coverage Statistics for Children in SEHSCT:
Completed Primary Immunisations by 24 months**

| Quarter* | Year | No. in cohort | **DTap/IPV/Hib/HepB | MMR1 | MenC | PCV Booster | Hib/MenC | MenB3 |
|-----------|------|---------------|---------------------|-------|-------|-------------|----------|-------|
| Jan-Mar | 2011 | 1066 | 98.4% | 91.3% | 97.3% | 92.4% | 94.7% | ~ |
| Apr-June | 2011 | 1157 | 98.1% | 91.4% | 96.9% | 91.8% | 94.4% | ~ |
| July-Sept | 2011 | 1226 | 98.5% | 92.4% | 97.0% | 93.6% | 95.6% | ~ |
| Oct-Dec | 2011 | 1132 | 97.7% | 92.8% | 96.5% | 94.2% | 95.1% | ~ |
| Jan-Mar | 2012 | 1096 | 98.6% | 93.8% | 97.7% | 94.3% | 95.3% | ~ |
| Apr-June | 2012 | 1113 | 98.4% | 95.0% | 97.2% | 95.6% | 95.5% | ~ |
| July-Sept | 2012 | 1190 | 98.7% | 95.1% | 97.6% | 95.5% | 95.9% | ~ |
| Oct-Dec | 2012 | 1183 | 98.7% | 95.9% | 97.6% | 96.3% | 96.1% | ~ |
| Jan-Mar | 2013 | 1077 | 98.1% | 95.7% | 97.0% | 96.4% | 96.4% | ~ |
| Apr-June | 2013 | 1120 | 99.0% | 96.3% | ~ | 96.3% | 96.9% | ~ |
| July-Sept | 2013 | 1231 | 98.4% | 95.7% | ~ | 95.9% | 96.3% | ~ |
| Oct-Dec | 2013 | 1147 | 98.8% | 96.7% | ~ | 97.6% | 97.7% | ~ |
| Jan-Mar | 2014 | 1154 | 99.0% | 97.2% | ~ | 97.9% | 98.2% | ~ |
| Apr-June | 2014 | 1106 | 99.2% | 96.0% | ~ | 96.1% | 96.1% | ~ |
| July-Sept | 2014 | 1110 | 98.6% | 96.2% | ~ | 96.3% | 96.4% | ~ |
| Oct-Dec | 2014 | 1158 | 99.2% | 96.7% | ~ | 97.8% | 97.2% | ~ |
| Jan-Mar | 2015 | 1082 | 97.0% | 94.5% | ~ | 94.8% | 94.7% | ~ |
| Apr-June | 2015 | 1092 | 98.5% | 96.6% | ~ | 96.4% | 96.2% | ~ |
| July-Sept | 2015 | 1157 | 98.9% | 96.1% | ~ | 95.9% | 95.9% | ~ |
| Oct-Dec | 2015 | 1028 | 98.2% | 95.6% | ~ | 96.3% | 96.1% | ~ |
| Jan-Mar | 2016 | 1082 | 98.4% | 95.6% | ~ | 95.7% | 95.6% | ~ |
| Apr-June | 2016 | 1070 | 97.9% | 95.5% | ~ | 96.3% | 96.3% | ~ |
| July-Sept | 2016 | 1201 | 97.9% | 94.6% | ~ | 95.3% | 95.6% | ~ |
| Oct-Dec | 2016 | 1085 | 98.0% | 95.4% | ~ | 96.2% | 96.2% | ~ |
| Jan-Mar | 2017 | 1028 | 98.0% | 94.9% | ~ | 94.7% | 94.4% | ~ |
| Apr-June | 2017 | 1078 | 97.2% | 94.0% | ~ | 95.1% | 94.2% | ~ |
| July-Sept | 2017 | 1217 | 97.9% | 95.5% | ~ | 95.9% | 95.4% | 95.5% |
| Oct-Dec | 2017 | 1115 | 98.4% | 95.2% | ~ | 96.1% | 95.6% | 95.5% |
| Jan-Mar | 2018 | 1049 | 98.3% | 95.2% | ~ | 95.3% | 95.0% | 94.9% |
| Apr-June | 2018 | 1097 | 97.4% | 92.9% | ~ | 93.5% | 93.7% | 93.6% |
| July-Sept | 2018 | 1166 | 97.7% | 93.7% | ~ | 94.1% | 93.7% | 93.8% |
| Oct-Dec | 2018 | 1063 | 97.1% | 93.7% | ~ | 93.9% | 93.7% | 93.5% |
| Jan-Mar | 2019 | 1056 | 96.7% | 92.2% | ~ | 92.9% | 92.9% | 92.8% |
| Apr-June | 2019 | 976 | 96.2% | 93.9% | ~ | 93.5% | 93.3% | 93.8% |
| July-Sept | 2019 | 1027 | 96.4% | 93.7% | ~ | 94.0% | 94.2% | 94.0% |
| Oct-Dec | 2019 | 1053 | 96.6% | 93.8% | ~ | 93.8% | 93.5% | 93.7% |
| Jan-Mar | 2020 | 975 | 95.9% | 93.3% | ~ | 93.9% | 93.6% | 93.6% |
| Apr-June | 2020 | 1041 | 95.8% | 92.3% | ~ | 93.1% | 92.4% | 92.6% |
| July-Sept | 2020 | 1101 | 95.6% | 92.3% | ~ | 92.9% | 92.6% | 92.3% |
| Oct-Dec | 2020 | 1036 | 97.4% | 93.0% | ~ | 93.1% | 93.0% | 92.9% |
| Jan-Mar | 2021 | 961 | 95.5% | 91.1% | ~ | 91.6% | 91.1% | 90.5% |
| Apr-June | 2021 | 1007 | 95.5% | 91.6% | ~ | 92.4% | 92.0% | 91.5% |
| July-Sept | 2021 | 1061 | 95.3% | 89.8% | ~ | 90.4% | 90.0% | 89.1% |
| Oct-Dec | 2021 | 967 | 94.3% | 90.3% | ~ | 90.3% | 90.1% | 88.3% |
| Jan-Mar | 2022 | 960 | 95.5% | 90.7% | ~ | 91.3% | 91.1% | 90.3% |
| Apr-June | 2022 | 907 | 93.6% | 91.4% | ~ | 91.5% | 91.8% | 90.0% |
| July-Sept | 2022 | 1024 | 92.5% | 88.2% | ~ | 88.3% | 88.3% | 87.4% |
| Oct-Dec | 2022 | 931 | 93.3% | 88.1% | ~ | 88.3% | 88.3% | 87.3% |
| Jan-Mar | 2023 | 920 | 93.0% | 89.6% | ~ | 89.9% | 90.0% | 89.7% |
| Apr-June | 2023 | 963 | 92.2% | 88.0% | ~ | 88.7% | 88.6% | 87.4% |
| Jul-Sept | 2023 | 1042 | 91.1% | 87.6% | ~ | 87.7% | 87.5% | 86.7% |
| Oct-Dec | 2023 | 1013 | 93.5% | 89.8% | ~ | 89.7% | 89.9% | 88.9% |
| Jan-Mar | 2024 | 948 | 90.7% | 87.2% | ~ | 87.7% | 87.3% | 86.2% |
| Apr-June | 2024 | 895 | 93.3% | 89.8% | ~ | 89.2% | 89.3% | 87.9% |
| Jul-Sept | 2024 | 985 | 93.5% | 91.0% | ~ | 90.7% | 90.7% | 89.3% |
| Oct-Dec | 2024 | 908 | 92.6% | 91.6% | ~ | 91.3% | 91.1% | 88.3% |
| Jan-Mar | 2025 | 885 | 93.0% | 91.2% | ~ | 91.5% | 91.3% | 87.7% |

* children were 24 months old during this quarter

****DTap/IPV/Hib/HepB**

Dip3 = Diphtheria (DTaP/IPV/Hib3 vaccine) (3 doses) replaced with (DTaP/IPV/Hib/HepB3 vaccine) from August 2017
Tet3 = Tetanus (DTaP/IPV/Hib3 vaccine) (3 doses) replaced with (DTaP/IPV/Hib/HepB3 vaccine) from August 2017
Pert3 = Pertussis (DTaP/IPV/Hib3 vaccine) (3 doses) replaced with (DTaP/IPV/Hib/HepB3 vaccine) from August 2017
Pol (IPV)3 = Polio (DTaP/IPV/Hib3 vaccine) (3 doses) replaced with (DTaP/IPV/Hib/HepB3 vaccine) from August 2017
Hib3 = *Haemophilus Influenzae* type b (DTaP/IPV/Hib3 vaccine) (3 doses) replaced with (DTaP/IPV/Hib/HepB3 vaccine) from August 2017
HepB3 = Hepatitis B (DTaP/IPV/Hib/HepB3 vaccine) (3 doses) (introduced in August 2017) Reporting commenced Jan-Mar 2020

Infant MenC = ~ Meningococcal serogroup C conjugate vaccine (2 doses under 12 months) reporting ceased in April 2013
PCV Booster = Pneumococcal conjugate booster vaccine (1 dose over 12 months) (introduced Sept 2006)
MMR1 = Measles, mumps, and rubella vaccine (1 dose)
Hib/MenC = Hib/MenC booster vaccine (1 dose) (introduced September 2006)
MenB3 = Meningococcal serogroup B vaccine (3 doses) (introduced Sept 2015)

**Vaccination Coverage Statistics for Children in NHSCT:
Completed Primary Immunisations by 24 months**

| Quarter* | Year | No. in cohort | **DTap/IPV/Hib/HepB | MMR1 | MenC | PCV Booster | Hib/MenC | MenB3 |
|-----------|------|---------------|---------------------|-------|-------|-------------|----------|-------|
| Jan-Mar | 2011 | 1377 | 99.5% | 94.9% | 98.3% | 95.4% | 97.4% | ~ |
| Apr-June | 2011 | 1438 | 98.4% | 93.7% | 97.0% | 94.1% | 96.6% | ~ |
| July-Sept | 2011 | 1498 | 99.2% | 93.7% | 98.0% | 94.6% | 96.1% | ~ |
| Oct-Dec | 2011 | 1487 | 98.9% | 93.4% | 97.6% | 94.8% | 96.4% | ~ |
| Jan-Mar | 2012 | 1550 | 98.5% | 94.5% | 97.1% | 95.9% | 96.8% | ~ |
| Apr-June | 2012 | 1510 | 99.1% | 96.3% | 97.5% | 97.0% | 96.9% | ~ |
| July-Sept | 2012 | 1544 | 98.8% | 95.1% | 97.6% | 95.3% | 95.5% | ~ |
| Oct-Dec | 2012 | 1565 | 99.2% | 96.6% | 98.0% | 97.1% | 97.1% | ~ |
| Jan-Mar | 2013 | 1490 | 98.8% | 95.1% | 97.7% | 95.8% | 96.2% | ~ |
| Apr-June | 2013 | 1477 | 98.8% | 96.4% | ~ | 96.6% | 96.5% | ~ |
| July-Sept | 2013 | 1550 | 99.0% | 96.2% | ~ | 96.1% | 96.3% | ~ |
| Oct-Dec | 2013 | 1455 | 99.0% | 97.0% | ~ | 97.3% | 97.5% | ~ |
| Jan-Mar | 2014 | 1466 | 98.6% | 95.6% | ~ | 96.2% | 96.3% | ~ |
| Apr-June | 2014 | 1456 | 98.6% | 95.5% | ~ | 96.1% | 95.9% | ~ |
| July-Sept | 2014 | 1553 | 99.0% | 97.1% | ~ | 97.4% | 97.1% | ~ |
| Oct-Dec | 2014 | 1536 | 98.6% | 95.0% | ~ | 96.2% | 96.4% | ~ |
| Jan-Mar | 2015 | 1408 | 99.1% | 93.6% | ~ | 94.9% | 94.7% | ~ |
| Apr-June | 2015 | 1442 | 98.2% | 96.0% | ~ | 96.0% | 96.1% | ~ |
| July-Sept | 2015 | 1558 | 98.3% | 96.7% | ~ | 96.5% | 96.7% | ~ |
| Oct-Dec | 2015 | 1448 | 98.8% | 96.5% | ~ | 97.3% | 97.2% | ~ |
| Jan-Mar | 2016 | 1429 | 98.5% | 96.4% | ~ | 97.5% | 96.7% | ~ |
| Apr-June | 2016 | 1393 | 98.3% | 96.6% | ~ | 96.8% | 96.7% | ~ |
| July-Sept | 2016 | 1571 | 98.2% | 95.4% | ~ | 96.1% | 96.2% | ~ |
| Oct-Dec | 2016 | 1515 | 98.7% | 95.6% | ~ | 95.9% | 95.8% | ~ |
| Jan-Mar | 2017 | 1391 | 98.3% | 95.3% | ~ | 95.9% | 95.8% | ~ |
| Apr-June | 2017 | 1443 | 99.2% | 95.4% | ~ | 96.1% | 96.0% | ~ |
| July-Sept | 2017 | 1541 | 98.4% | 94.4% | ~ | 94.9% | 95.2% | 94.2% |
| Oct-Dec | 2017 | 1490 | 98.5% | 95.2% | ~ | 96.0% | 96.0% | 95.3% |
| Jan-Mar | 2018 | 1328 | 98.9% | 95.7% | ~ | 96.8% | 96.7% | 96.2% |
| Apr-June | 2018 | 1430 | 98.0% | 94.4% | ~ | 95.4% | 95.0% | 94.9% |
| July-Sept | 2018 | 1506 | 97.9% | 95.8% | ~ | 96.5% | 96.3% | 96.1% |
| Oct-Dec | 2018 | 1487 | 97.6% | 93.5% | ~ | 93.7% | 93.8% | 93.5% |
| Jan-Mar | 2019 | 1371 | 97.1% | 92.6% | ~ | 93.2% | 93.1% | 93.0% |
| Apr-June | 2019 | 1343 | 97.2% | 93.0% | ~ | 93.4% | 93.4% | 93.2% |
| July-Sept | 2019 | 1505 | 97.3% | 94.1% | ~ | 94.3% | 94.4% | 94.0% |
| Oct-Dec | 2019 | 1398 | 97.4% | 95.1% | ~ | 95.6% | 95.6% | 95.1% |
| Jan-Mar | 2020 | 1239 | 96.8% | 93.5% | ~ | 93.6% | 93.5% | 93.3% |
| Apr-June | 2020 | 1380 | 96.7% | 94.3% | ~ | 95.0% | 94.5% | 94.6% |
| July-Sept | 2020 | 1396 | 96.8% | 94.1% | ~ | 94.8% | 94.8% | 94.5% |
| Oct-Dec | 2020 | 1355 | 96.5% | 93.7% | ~ | 93.9% | 93.8% | 93.4% |
| Jan-Mar | 2021 | 1309 | 97.3% | 93.4% | ~ | 94.1% | 94.1% | 93.9% |
| Apr-June | 2021 | 1314 | 97.6% | 95.0% | ~ | 95.7% | 95.5% | 95.1% |
| July-Sept | 2021 | 1427 | 97.1% | 93.9% | ~ | 94.3% | 94.5% | 93.7% |
| Oct-Dec | 2021 | 1366 | 96.6% | 93.3% | ~ | 93.6% | 93.6% | 92.5% |
| Jan-Mar | 2022 | 1229 | 96.7% | 94.1% | ~ | 94.4% | 94.5% | 93.7% |
| Apr-June | 2022 | 1302 | 96.2% | 92.7% | ~ | 93.0% | 93.1% | 92.5% |
| July-Sept | 2022 | 1392 | 96.3% | 92.2% | ~ | 92.6% | 92.5% | 92.0% |
| Oct-Dec | 2022 | 1264 | 98.1% | 93.7% | ~ | 94.1% | 93.8% | 93.8% |
| Jan-Mar | 2023 | 1276 | 95.7% | 90.7% | ~ | 91.3% | 91.3% | 91.1% |
| Apr-June | 2023 | 1300 | 96.8% | 92.8% | ~ | 93.5% | 93.6% | 92.7% |
| Jul-Sept | 2023 | 1387 | 95.2% | 91.3% | ~ | 91.8% | 91.9% | 91.3% |
| Oct-Dec | 2023 | 1333 | 95.1% | 90.5% | ~ | 91.1% | 91.2% | 90.9% |
| Jan-Mar | 2024 | 1243 | 96.3% | 91.1% | ~ | 91.2% | 91.4% | 90.9% |
| Apr-June | 2024 | 1231 | 95.0% | 92.0% | ~ | 92.2% | 92.6% | 91.3% |
| Jul-Sept | 2024 | 1337 | 95.5% | 92.5% | ~ | 92.2% | 92.4% | 91.6% |
| Oct-Dec | 2024 | 1270 | 94.8% | 90.9% | ~ | 95.7% | 90.9% | 90.6% |
| Jan-Mar | 2025 | 1152 | 93.8% | 90.0% | ~ | 89.8% | 89.8% | 89.3% |

* children were 24 months old during this quarter

****DTap/IPV/Hib/HepB**

| | |
|---------------|--|
| Dip3 = | Diphtheria (DTaP/IPV/Hib3 vaccine) (3 doses) replaced with (DTaP/IPV/Hib/HepB3 vaccine) from August 2017 |
| Tet3 = | Tetanus (DTaP/IPV/Hib3 vaccine) (3 doses) replaced with (DTaP/IPV/Hib/HepB3 vaccine) from August 2017 |
| Pert3 = | Pertussis (DTaP/IPV/Hib3 vaccine) (3 doses) replaced with (DTaP/IPV/Hib/HepB3 vaccine) from August 2017 |
| Pol (IPV)3 = | Polio (DTaP/IPV/Hib3 vaccine) (3 doses) replaced with (DTaP/IPV/Hib/HepB3 vaccine) from August 2017 |
| Hib3 = | <i>Haemophilus Influenzae</i> type b (DTaP/IPV/Hib3 vaccine) (3 doses) replaced with (DTaP/IPV/Hib/HepB3 vaccine) from August 2017 |
| HepB3 = | Hepatitis B (DTaP/IPV/Hib/HepB3 vaccine) (3 doses) (introduced in August 2017) Reporting commenced Jan-Mar 2020 |
| | |
| Infant MenC = | ~ Meningococcal serogroup C conjugate vaccine (2 doses under 12 months) <u>reporting ceased in April 2013.</u> |
| PCV Booster = | Pneumococcal conjugate booster vaccine (1 dose over 12 months) (introduced Sept 2006) |
| MMR1 = | Measles, mumps, and rubella vaccine (1 dose) |
| Hib/MenC = | Hib/MenC booster vaccine (1 dose) (introduced September 2006) |
| MenB3 = | Meningococcal serogroup B vaccine (3 doses) (introduced Sept 2015) |

Vaccination Coverage Statistics for Children in SHSCT:
Completed Primary Immunisations by 24 months

| Quarter* | Year | No. in cohort | **DTaP/IPV/Hib/HepB | MMR1 | MenC | PCV Booster | Hib/MenC | MenB3 |
|-----------|------|---------------|---------------------|-------|-------|-------------|----------|-------|
| Jan-Mar | 2011 | 1367 | 99.4% | 94.1% | 98.7% | 94.4% | 97.0% | ~ |
| Apr-June | 2011 | 1391 | 99.5% | 94.5% | 98.0% | 94.8% | 96.6% | ~ |
| July-Sept | 2011 | 1415 | 98.7% | 94.3% | 96.9% | 94.3% | 96.8% | ~ |
| Oct-Dec | 2011 | 1417 | 98.9% | 95.1% | 97.2% | 95.3% | 96.6% | ~ |
| Jan-Mar | 2012 | 1410 | 99.1% | 94.8% | 97.7% | 95.7% | 96.5% | ~ |
| Apr-June | 2012 | 1356 | 98.8% | 96.5% | 96.8% | 96.8% | 96.8% | ~ |
| July-Sept | 2012 | 1474 | 99.1% | 97.1% | 97.4% | 97.0% | 97.0% | ~ |
| Oct-Dec | 2012 | 1440 | 99.2% | 96.7% | 98.1% | 96.9% | 97.4% | ~ |
| Jan-Mar | 2013 | 1369 | 98.8% | 96.2% | 97.7% | 96.4% | 96.1% | ~ |
| Apr-June | 2013 | 1291 | 98.8% | 96.6% | ~ | 96.7% | 97.1% | ~ |
| July-Sept | 2013 | 1447 | 99.0% | 96.2% | ~ | 96.0% | 96.3% | ~ |
| Oct-Dec | 2013 | 1389 | 99.1% | 96.7% | ~ | 96.5% | 96.5% | ~ |
| Jan-Mar | 2014 | 1357 | 99.1% | 96.8% | ~ | 96.6% | 96.6% | ~ |
| Apr-June | 2014 | 1424 | 98.9% | 97.4% | ~ | 97.1% | 97.3% | ~ |
| July-Sept | 2014 | 1542 | 99.0% | 97.5% | ~ | 97.3% | 97.4% | ~ |
| Oct-Dec | 2014 | 1430 | 98.6% | 95.9% | ~ | 95.5% | 95.9% | ~ |
| Jan-Mar | 2015 | 1314 | 98.6% | 96.7% | ~ | 96.2% | 96.3% | ~ |
| Apr-June | 2015 | 1329 | 98.9% | 97.5% | ~ | 96.8% | 97.0% | ~ |
| July-Sept | 2015 | 1420 | 98.7% | 96.3% | ~ | 96.4% | 96.3% | ~ |
| Oct-Dec | 2015 | 1377 | 99.1% | 96.4% | ~ | 96.8% | 96.7% | ~ |
| Jan-Mar | 2016 | 1360 | 99.0% | 97.7% | ~ | 97.0% | 97.2% | ~ |
| Apr-June | 2016 | 1389 | 98.1% | 95.6% | ~ | 95.7% | 96.0% | ~ |
| July-Sept | 2016 | 1437 | 98.2% | 95.8% | ~ | 95.2% | 95.5% | ~ |
| Oct-Dec | 2016 | 1403 | 98.4% | 96.5% | ~ | 95.6% | 95.7% | ~ |
| Jan-Mar | 2017 | 1319 | 98.4% | 96.7% | ~ | 96.9% | 96.8% | ~ |
| Apr-June | 2017 | 1322 | 98.4% | 96.3% | ~ | 95.8% | 96.1% | ~ |
| July-Sept | 2017 | 1501 | 97.9% | 95.1% | ~ | 95.1% | 95.4% | 94.2% |
| Oct-Dec | 2017 | 1458 | 98.1% | 94.9% | ~ | 95.3% | 95.2% | 95.1% |
| Jan-Mar | 2018 | 1369 | 98.2% | 94.7% | ~ | 94.8% | 95.3% | 94.5% |
| Apr-June | 2018 | 1381 | 98.7% | 95.6% | ~ | 94.6% | 94.9% | 94.1% |
| July-Sept | 2018 | 1466 | 97.5% | 94.1% | ~ | 94.3% | 94.3% | 93.9% |
| Oct-Dec | 2018 | 1398 | 97.3% | 93.9% | ~ | 94.1% | 94.3% | 93.6% |
| Jan-Mar | 2019 | 1274 | 97.2% | 92.8% | ~ | 93.2% | 93.1% | 92.6% |
| Apr-June | 2019 | 1383 | 97.2% | 94.2% | ~ | 94.2% | 94.1% | 94.1% |
| July-Sept | 2019 | 1501 | 96.8% | 93.9% | ~ | 94.0% | 93.7% | 93.7% |
| Oct-Dec | 2019 | 1317 | 97.3% | 94.2% | ~ | 94.2% | 94.0% | 93.8% |
| Jan-Mar | 2020 | 1263 | 97.1% | 94.2% | ~ | 94.4% | 94.6% | 93.6% |
| Apr-June | 2020 | 1353 | 95.8% | 93.1% | ~ | 93.1% | 93.3% | 93.3% |
| July-Sept | 2020 | 1435 | 96.2% | 93.2% | ~ | 93.0% | 92.7% | 92.1% |
| Oct-Dec | 2020 | 1360 | 96.5% | 93.2% | ~ | 93.2% | 93.1% | 92.9% |
| Jan-Mar | 2021 | 1259 | 96.9% | 93.8% | ~ | 94.3% | 94.0% | 93.6% |
| Apr-June | 2021 | 1290 | 95.9% | 93.7% | ~ | 93.5% | 93.3% | 92.6% |
| July-Sept | 2021 | 1413 | 96.2% | 92.8% | ~ | 92.9% | 93.2% | 92.2% |
| Oct-Dec | 2021 | 1344 | 95.9% | 93.1% | ~ | 93.3% | 93.2% | 92.9% |
| Jan-Mar | 2022 | 1218 | 96.6% | 93.8% | ~ | 94.4% | 93.8% | 93.4% |
| Apr-June | 2022 | 1172 | 95.9% | 92.2% | ~ | 92.3% | 91.9% | 91.5% |
| July-Sept | 2022 | 1308 | 96.0% | 91.6% | ~ | 91.7% | 91.6% | 91.2% |
| Oct-Dec | 2022 | 1251 | 95.3% | 91.4% | ~ | 91.7% | 91.8% | 91.3% |
| Jan-Mar | 2023 | 1244 | 96.9% | 93.5% | ~ | 93.7% | 93.5% | 93.4% |
| Apr-June | 2023 | 1230 | 96.4% | 93.0% | ~ | 93.0% | 92.6% | 92.4% |
| Jul-Sept | 2023 | 1435 | 94.9% | 89.5% | ~ | 90.0% | 89.8% | 89.5% |
| Oct-Dec | 2023 | 1319 | 95.4% | 91.7% | ~ | 91.7% | 91.7% | 90.6% |
| Jan-Mar | 2024 | 1232 | 95.3% | 91.6% | ~ | 91.8% | 92.0% | 91.3% |
| Apr-June | 2024 | 1227 | 95.0% | 91.0% | ~ | 91.0% | 91.1% | 90.9% |
| Jul-Sept | 2024 | 1260 | 93.9% | 91.1% | ~ | 91.4% | 90.9% | 90.2% |
| Oct-Dec | 2024 | 1199 | 93.1% | 88.6% | ~ | 94.0% | 88.4% | 87.5% |
| Jan-Mar | 2025 | 1134 | 94.4% | 89.7% | ~ | 90.2% | 90.0% | 89.3% |

* children were 24 months old during this quarter

****DTaP/IPV/Hib/HepB**

Dip3 = Diphtheria (DTaP/IPV/Hib3 vaccine) (3 doses) replaced with (DTaP/IPV/Hib/HepB3 vaccine) from August 2017
Tet3 = Tetanus (DTaP/IPV/Hib3 vaccine) (3 doses) replaced with (DTaP/IPV/Hib/HepB3 vaccine) from August 2017
Pert3 = Pertussis (DTaP/IPV/Hib3 vaccine) (3 doses) replaced with (DTaP/IPV/Hib/HepB3 vaccine) from August 2017
Pol (IPV)3 = Polio (DTaP/IPV/Hib3 vaccine) (3 doses) replaced with (DTaP/IPV/Hib/HepB3 vaccine) from August 2017
Hib3 = *Haemophilus Influenzae* type b (DTaP/IPV/Hib3 vaccine) (3 doses) replaced with (DTaP/IPV/Hib/HepB3 vaccine)
HepB3 = Hepatitis B (DTaP/IPV/Hib/HepB3 vaccine) (3 doses) (introduced in August 2017) Reporting commenced Jan-Ma

Infant MenC = ~ Meningococcal serogroup C conjugate vaccine (2 doses under 12 months) reporting ceased in April 2013
PCV Booster = Pneumococcal conjugate booster vaccine (1 dose over 12 months) (introduced Sept 2006)
MMR1 = Measles, mumps, and rubella vaccine (1 dose)
Hib/MenC = Hib/MenC booster vaccine (1 dose) (introduced September 2006)

**Vaccination Coverage Statistics for Children in WHSCT:
Completed Primary Immunisations by 24 months**

| Quarter* | Year | No. in cohort | **DTaP/IPV/Hib/HepB | MMR1 | MenC | PCV Booster | Hib/MenC | MenB3 |
|-----------|------|---------------|---------------------|-------|-------|-------------|----------|-------|
| Jan-Mar | 2011 | 1087 | 98.7% | 95.3% | 97.5% | 96.0% | 96.9% | ~ |
| Apr-June | 2011 | 1018 | 98.9% | 94.4% | 97.5% | 94.8% | 95.8% | ~ |
| July-Sept | 2011 | 1079 | 99.1% | 94.9% | 97.8% | 95.5% | 96.5% | ~ |
| Oct-Dec | 2011 | 1051 | 99.1% | 95.8% | 97.8% | 96.6% | 97.5% | ~ |
| Jan-Mar | 2012 | 1060 | 99.0% | 95.3% | 98.2% | 97.0% | 97.9% | ~ |
| Apr-June | 2012 | 1028 | 98.7% | 95.7% | 98.1% | 96.0% | 95.7% | ~ |
| July-Sept | 2012 | 1079 | 99.4% | 97.1% | 99.0% | 97.5% | 97.6% | ~ |
| Oct-Dec | 2012 | 1061 | 99.1% | 96.8% | 97.9% | 98.0% | 97.9% | ~ |
| Jan-Mar | 2013 | 1065 | 99.0% | 96.6% | 98.1% | 97.0% | 97.0% | ~ |
| Apr-June | 2013 | 1047 | 98.9% | 97.2% | ~ | 97.8% | 97.9% | ~ |
| July-Sept | 2013 | 1084 | 99.4% | 97.4% | ~ | 97.3% | 97.0% | ~ |
| Oct-Dec | 2013 | 1055 | 98.8% | 97.3% | ~ | 97.4% | 97.6% | ~ |
| Jan-Mar | 2014 | 1024 | 98.8% | 97.3% | ~ | 97.0% | 96.9% | ~ |
| Apr-June | 2014 | 1036 | 99.8% | 98.8% | ~ | 98.6% | 98.6% | ~ |
| July-Sept | 2014 | 1027 | 99.6% | 97.0% | ~ | 97.5% | 97.3% | ~ |
| Oct-Dec | 2014 | 1079 | 98.5% | 96.7% | ~ | 96.8% | 97.1% | ~ |
| Jan-Mar | 2015 | 901 | 98.6% | 97.1% | ~ | 97.3% | 97.1% | ~ |
| Apr-June | 2015 | 936 | 98.8% | 97.2% | ~ | 97.6% | 97.4% | ~ |
| July-Sept | 2015 | 1073 | 99.1% | 96.2% | ~ | 96.8% | 96.8% | ~ |
| Oct-Dec | 2015 | 988 | 99.1% | 96.8% | ~ | 97.5% | 97.4% | ~ |
| Jan-Mar | 2016 | 955 | 98.3% | 95.8% | ~ | 98.1% | 96.5% | ~ |
| Apr-June | 2016 | 971 | 98.2% | 95.6% | ~ | 97.0% | 95.9% | ~ |
| July-Sept | 2016 | 1122 | 98.7% | 96.4% | ~ | 97.1% | 97.1% | ~ |
| Oct-Dec | 2016 | 1014 | 98.8% | 96.1% | ~ | 98.2% | 96.8% | ~ |
| Jan-Mar | 2017 | 922 | 98.6% | 95.9% | ~ | 96.5% | 96.4% | ~ |
| Apr-June | 2017 | 973 | 98.4% | 95.7% | ~ | 96.3% | 96.3% | ~ |
| July-Sept | 2017 | 1114 | 98.7% | 96.8% | ~ | 97.4% | 97.5% | 96.8% |
| Oct-Dec | 2017 | 1048 | 98.1% | 94.5% | ~ | 96.0% | 95.5% | 95.9% |
| Jan-Mar | 2018 | 977 | 98.6% | 95.5% | ~ | 96.6% | 96.5% | 96.0% |
| Apr-June | 2018 | 996 | 97.9% | 94.3% | ~ | 95.6% | 95.3% | 94.8% |
| July-Sept | 2018 | 1064 | 98.6% | 94.8% | ~ | 96.1% | 96.3% | 95.9% |
| Oct-Dec | 2018 | 991 | 97.4% | 93.3% | ~ | 93.8% | 93.5% | 93.8% |
| Jan-Mar | 2019 | 962 | 97.5% | 92.3% | ~ | 96.9% | 93.0% | 92.4% |
| Apr-June | 2019 | 959 | 97.0% | 91.4% | ~ | 92.5% | 92.3% | 92.5% |
| July-Sept | 2019 | 1021 | 96.4% | 92.8% | ~ | 93.4% | 92.8% | 93.1% |
| Oct-Dec | 2019 | 1035 | 96.6% | 92.0% | ~ | 95.6% | 92.9% | 92.6% |
| Jan-Mar | 2020 | 940 | 95.6% | 93.3% | ~ | 93.4% | 93.4% | 93.3% |
| Apr-June | 2020 | 975 | 96.7% | 94.2% | ~ | 94.1% | 93.8% | 94.4% |
| July-Sept | 2020 | 987 | 97.7% | 94.2% | ~ | 95.1% | 94.9% | 94.8% |
| Oct-Dec | 2020 | 925 | 96.4% | 93.4% | ~ | 94.5% | 94.4% | 94.1% |
| Jan-Mar | 2021 | 936 | 97.2% | 92.8% | ~ | 93.5% | 93.3% | 93.2% |
| Apr-June | 2021 | 885 | 96.8% | 95.1% | ~ | 95.6% | 95.6% | 95.1% |
| July-Sept | 2021 | 965 | 95.8% | 94.8% | ~ | 95.9% | 95.4% | 94.8% |
| Oct-Dec | 2021 | 919 | 95.9% | 95.0% | ~ | 95.5% | 95.2% | 95.1% |
| Jan-Mar | 2022 | 925 | 95.9% | 95.0% | ~ | 94.7% | 94.9% | 94.9% |
| Apr-June | 2022 | 886 | 97.0% | 94.6% | ~ | 94.8% | 95.0% | 94.1% |
| July-Sept | 2022 | 924 | 95.8% | 93.4% | ~ | 94.3% | 93.8% | 93.7% |
| Oct-Dec | 2022 | 973 | 95.7% | 93.1% | ~ | 96.3% | 93.5% | 93.3% |
| Jan-Mar | 2023 | 929 | 95.4% | 92.5% | ~ | 93.2% | 93.2% | 92.5% |
| Apr-June | 2023 | 889 | 96.0% | 91.7% | ~ | 92.9% | 93.3% | 92.6% |
| Jul-Sept | 2023 | 1030 | 94.8% | 92.0% | ~ | 92.9% | 92.6% | 92.1% |
| Oct-Dec | 2023 | 925 | 95.8% | 92.3% | ~ | 93.2% | 92.6% | 92.3% |
| Jan-Mar | 2024 | 845 | 95.0% | 90.4% | ~ | 91.0% | 90.8% | 90.2% |
| Apr-June | 2024 | 840 | 93.6% | 90.7% | ~ | 91.4% | 91.4% | 91.3% |
| Jul-Sept | 2024 | 873 | 95.8% | 92.7% | ~ | 96.9% | 93.6% | 92.9% |
| Oct-Dec | 2024 | 881 | 93.5% | 90.1% | ~ | 90.5% | 90.4% | 90.0% |
| Jan-Mar | 2025 | 829 | 93.5% | 90.2% | ~ | 91.1% | 90.5% | 89.9% |

* children were 24 months old during this quarter

****DTaP/IPV/Hib/HepB**

| | |
|--------------|--|
| Dip3 = | Diphtheria (DTaP/IPV/Hib3 vaccine) (3 doses) replaced with (DTaP/IPV/Hib/HepB3 vaccine) from August 2017 |
| Tet3 = | Tetanus (DTaP/IPV/Hib3 vaccine) (3 doses) replaced with (DTaP/IPV/Hib/HepB3 vaccine) from August 2017 |
| Pert3 = | Pertussis (DTaP/IPV/Hib3 vaccine) (3 doses) replaced with (DTaP/IPV/Hib/HepB3 vaccine) from August 2017 |
| Pol (IPV)3 = | Polio (DTaP/IPV/Hib3 vaccine) (3 doses) replaced with (DTaP/IPV/Hib/HepB3 vaccine) from August 2017 |
| Hib3 = | <i>Haemophilus Influenzae</i> type b (DTaP/IPV/Hib3 vaccine) (3 doses) replaced with (DTaP/IPV/Hib/HepB3 vaccine) from August 2017 |
| HepB3 = | Hepatitis B (DTaP/IPV/Hib/HepB3 vaccine) (3 doses) (introduced in August 2017)Reporting commenced Jan-Mar 2020 |

Infant MenC = ~ Meningococcal serogroup C conjugate vaccine (2 doses under 12 months) reporting ceased in April 2013.

PCV Booster = Pneumococcal conjugate booster vaccine (1 dose over 12 months) (introduced Sept 2006)

MMR1 = Measles, mumps, and rubella vaccine (1 dose)

Hib/MenC = Hib/MenC booster vaccine (1 dose) (introduced September 2006)

MenB3 = Meningococcal serogroup B vaccine (3 doses) (introduced Sept 2015)